Back
ESC Premium Access

Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial

Session: Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy
Topic: Hypertrophic Cardiomyopathy
Speaker: Doctor M. Desai (Cleveland, US)
Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Milind Desai

Cleveland Clinic, Cleveland (United States of America)
16 presentations
0 follower

3 more presentations in this session

Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy

Speaker: Doctor A. Milazzo (Florence, IT)

Access
Abstract
Slides
Video
Thumbnail

A comprehensive evaluation of available evidence of mavacamten in obstructive HCM: a meta-analysis of randomised controlled trials.

Speaker: Doctor A. Elmorsy (Tanta, EG)

Access
Abstract
Slides
Video
Thumbnail

Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?

Speaker: Doctor M. Lima (Lisbon, PT)

Access
Abstract
Slides
Video
Thumbnail

Access the full session

Cardiac myosin inhibitors for treatment of hypertrophic obstructive cardiomyopathy

Speakers: Doctor M. Desai, Doctor A. Milazzo, Doctor A. Elmorsy, Doctor M. Lima
Access
Video
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources